Effect of Oxyntomodulin, Glucagon, GLP-1 and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite and Resting Energy Expenditure

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Effect of Oxyntomodulin, Glucagon, GLP-1 and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite and Resting Energy Expenditure. / Bagger, Jonatan I; Holst, Jens J; Hartmann, Bolette; Andersen, Birgitte; Knop, Filip K; Vilsbøll, Tina.

In: The Journal of Clinical Endocrinology & Metabolism, Vol. 100, No. 12, 2015, p. 4541–4552.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bagger, JI, Holst, JJ, Hartmann, B, Andersen, B, Knop, FK & Vilsbøll, T 2015, 'Effect of Oxyntomodulin, Glucagon, GLP-1 and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite and Resting Energy Expenditure', The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 12, pp. 4541–4552. https://doi.org/10.1210/jc.2015-2335

APA

Bagger, J. I., Holst, J. J., Hartmann, B., Andersen, B., Knop, F. K., & Vilsbøll, T. (2015). Effect of Oxyntomodulin, Glucagon, GLP-1 and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite and Resting Energy Expenditure. The Journal of Clinical Endocrinology & Metabolism, 100(12), 4541–4552. https://doi.org/10.1210/jc.2015-2335

Vancouver

Bagger JI, Holst JJ, Hartmann B, Andersen B, Knop FK, Vilsbøll T. Effect of Oxyntomodulin, Glucagon, GLP-1 and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite and Resting Energy Expenditure. The Journal of Clinical Endocrinology & Metabolism. 2015;100(12):4541–4552. https://doi.org/10.1210/jc.2015-2335

Author

Bagger, Jonatan I ; Holst, Jens J ; Hartmann, Bolette ; Andersen, Birgitte ; Knop, Filip K ; Vilsbøll, Tina. / Effect of Oxyntomodulin, Glucagon, GLP-1 and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite and Resting Energy Expenditure. In: The Journal of Clinical Endocrinology & Metabolism. 2015 ; Vol. 100, No. 12. pp. 4541–4552.

Bibtex

@article{96760698f2bc4f7a81d357e6ced9483c,
title = "Effect of Oxyntomodulin, Glucagon, GLP-1 and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite and Resting Energy Expenditure",
abstract = "Context: The gut hormone, oxyntomodulin, is a proglucagon product with body weight-lowering potential. It binds to both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor; however, the mechanism behind the body weight-lowering effect remains elusive. Objective: We wanted to delineate the contributions of separate and combined GLP-1 receptor and glucagon receptor activation to the body weight-reducing mechanisms of oxyntomodulin. Design: This was a double-blinded, randomized, crossover study. Setting: The study was conducted at a specialized research unit.Participants: Fifteen young healthy male volunteers (aged 22 [range 18–32] y; body mass index 23 [21–26] kg/m2; fasting plasma glucose 5.1 [4.4–5.4] mmol/L; and glycated hemoglobin A1c 40 (37–42) mmol/mol).Interventions: Five 4-hour liquid meal tests during the infusion of saline, GLP-1 (1 pmol × kg−1 × min−1), glucagon (0.86 pmol × kg−1 × min−1), oxyntomodulin (3 pmol × kg−1 × min−1), or glucagon+GLP-1 (same doses). Main Outcome Measures: We evaluated resting energy expenditure (measured as oxygen uptake, gastric emptying (GE), composite appetite scores (CAS), and food intake. Results: Oxyntomodulin, GLP-1, and GLP-1+glucagon slowed GE and reduced CAS, whereas glucagon did not affect GE and CAS. All infusions caused a similar decrease in food intake compared with saline (total intake (g [95{\%} confidence interval]), saline 811 [729, 892], GLP-1 669 [586, 750], glucagon 686 [604, 768], oxyntomodulin 689 [608, 771], and glucagon+GLP-1 688 [606, 769]). Oxygen uptake did not change significantly from baseline in response to any peptide infusion compared with saline. Conclusions: Oxyntomodulin, GLP-1, and glucagon decreased food intake but with no additional effect of combining GLP-1 and glucagon. - See more at: http://press.endocrine.org/doi/10.1210/jc.2015-2335#sthash.EFincsdL.dpuf",
author = "Bagger, {Jonatan I} and Holst, {Jens J} and Bolette Hartmann and Birgitte Andersen and Knop, {Filip K} and Tina Vilsb{\o}ll",
year = "2015",
doi = "10.1210/jc.2015-2335",
language = "English",
volume = "100",
pages = "4541–4552",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "12",

}

RIS

TY - JOUR

T1 - Effect of Oxyntomodulin, Glucagon, GLP-1 and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite and Resting Energy Expenditure

AU - Bagger, Jonatan I

AU - Holst, Jens J

AU - Hartmann, Bolette

AU - Andersen, Birgitte

AU - Knop, Filip K

AU - Vilsbøll, Tina

PY - 2015

Y1 - 2015

N2 - Context: The gut hormone, oxyntomodulin, is a proglucagon product with body weight-lowering potential. It binds to both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor; however, the mechanism behind the body weight-lowering effect remains elusive. Objective: We wanted to delineate the contributions of separate and combined GLP-1 receptor and glucagon receptor activation to the body weight-reducing mechanisms of oxyntomodulin. Design: This was a double-blinded, randomized, crossover study. Setting: The study was conducted at a specialized research unit.Participants: Fifteen young healthy male volunteers (aged 22 [range 18–32] y; body mass index 23 [21–26] kg/m2; fasting plasma glucose 5.1 [4.4–5.4] mmol/L; and glycated hemoglobin A1c 40 (37–42) mmol/mol).Interventions: Five 4-hour liquid meal tests during the infusion of saline, GLP-1 (1 pmol × kg−1 × min−1), glucagon (0.86 pmol × kg−1 × min−1), oxyntomodulin (3 pmol × kg−1 × min−1), or glucagon+GLP-1 (same doses). Main Outcome Measures: We evaluated resting energy expenditure (measured as oxygen uptake, gastric emptying (GE), composite appetite scores (CAS), and food intake. Results: Oxyntomodulin, GLP-1, and GLP-1+glucagon slowed GE and reduced CAS, whereas glucagon did not affect GE and CAS. All infusions caused a similar decrease in food intake compared with saline (total intake (g [95% confidence interval]), saline 811 [729, 892], GLP-1 669 [586, 750], glucagon 686 [604, 768], oxyntomodulin 689 [608, 771], and glucagon+GLP-1 688 [606, 769]). Oxygen uptake did not change significantly from baseline in response to any peptide infusion compared with saline. Conclusions: Oxyntomodulin, GLP-1, and glucagon decreased food intake but with no additional effect of combining GLP-1 and glucagon. - See more at: http://press.endocrine.org/doi/10.1210/jc.2015-2335#sthash.EFincsdL.dpuf

AB - Context: The gut hormone, oxyntomodulin, is a proglucagon product with body weight-lowering potential. It binds to both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor; however, the mechanism behind the body weight-lowering effect remains elusive. Objective: We wanted to delineate the contributions of separate and combined GLP-1 receptor and glucagon receptor activation to the body weight-reducing mechanisms of oxyntomodulin. Design: This was a double-blinded, randomized, crossover study. Setting: The study was conducted at a specialized research unit.Participants: Fifteen young healthy male volunteers (aged 22 [range 18–32] y; body mass index 23 [21–26] kg/m2; fasting plasma glucose 5.1 [4.4–5.4] mmol/L; and glycated hemoglobin A1c 40 (37–42) mmol/mol).Interventions: Five 4-hour liquid meal tests during the infusion of saline, GLP-1 (1 pmol × kg−1 × min−1), glucagon (0.86 pmol × kg−1 × min−1), oxyntomodulin (3 pmol × kg−1 × min−1), or glucagon+GLP-1 (same doses). Main Outcome Measures: We evaluated resting energy expenditure (measured as oxygen uptake, gastric emptying (GE), composite appetite scores (CAS), and food intake. Results: Oxyntomodulin, GLP-1, and GLP-1+glucagon slowed GE and reduced CAS, whereas glucagon did not affect GE and CAS. All infusions caused a similar decrease in food intake compared with saline (total intake (g [95% confidence interval]), saline 811 [729, 892], GLP-1 669 [586, 750], glucagon 686 [604, 768], oxyntomodulin 689 [608, 771], and glucagon+GLP-1 688 [606, 769]). Oxygen uptake did not change significantly from baseline in response to any peptide infusion compared with saline. Conclusions: Oxyntomodulin, GLP-1, and glucagon decreased food intake but with no additional effect of combining GLP-1 and glucagon. - See more at: http://press.endocrine.org/doi/10.1210/jc.2015-2335#sthash.EFincsdL.dpuf

U2 - 10.1210/jc.2015-2335

DO - 10.1210/jc.2015-2335

M3 - Journal article

C2 - 26445112

VL - 100

SP - 4541

EP - 4552

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -

ID: 150706435